Weighted Average Number of Shares Outstanding, Basic of Nurix Therapeutics, Inc. from 31 May 2020 to 30 Nov 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Nurix Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 May 2020 to 30 Nov 2025.
  • Nurix Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 30 Nov 2025 was 86,666,907, a 29% increase year-over-year.
  • Nurix Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 86,666,907, a 29% increase from 2024.
  • Nurix Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 67,120,266, a 24% increase from 2023.
  • Nurix Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 54,337,901, a 12% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Nurix Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 86,666,907 +19,546,641 +29% 01 Sep 2025 30 Nov 2025 10-K 28 Jan 2026 2025 FY
Q3 2025 84,159,336 +11,379,955 +16% 01 Jun 2025 31 Aug 2025 10-Q 09 Oct 2025 2025 Q3
Q2 2025 83,882,477 +21,504,926 +34% 01 Mar 2025 31 May 2025 10-Q 09 Jul 2025 2025 Q2
Q1 2025 83,560,795 +28,657,388 +52% 01 Dec 2024 28 Feb 2025 10-Q 08 Apr 2025 2025 Q1
Q4 2024 67,120,266 +12,782,365 +24% 01 Sep 2024 30 Nov 2024 10-K 28 Jan 2026 2025 FY
Q3 2024 72,779,381 +18,388,522 +34% 01 Jun 2024 31 Aug 2024 10-Q 09 Oct 2025 2025 Q3
Q2 2024 62,377,551 +8,118,506 +15% 01 Mar 2024 31 May 2024 10-Q 09 Jul 2025 2025 Q2
Q1 2024 54,903,407 +875,169 +1.6% 01 Dec 2023 29 Feb 2024 10-Q 08 Apr 2025 2025 Q1
Q4 2023 54,337,901 +5,729,911 +12% 01 Sep 2023 30 Nov 2023 10-K 28 Jan 2026 2025 FY
Q3 2023 54,390,859 +3,522,317 +6.9% 01 Jun 2023 31 Aug 2023 10-Q 11 Oct 2024 2024 Q3
Q2 2023 54,259,045 +9,360,636 +21% 01 Mar 2023 31 May 2023 10-Q 11 Jul 2024 2024 Q2
Q1 2023 54,028,238 +9,334,426 +21% 01 Dec 2022 28 Feb 2023 10-Q 10 Apr 2024 2024 Q1
Q4 2022 48,607,990 01 Sep 2022 30 Nov 2022 10-K 28 Jan 2025 2024 FY
Q3 2022 50,868,542 +6,494,153 +15% 01 Jun 2022 31 Aug 2022 10-Q 12 Oct 2023 2023 Q3
Q2 2022 44,898,409 +1,094,343 +2.5% 01 Mar 2022 31 May 2022 10-Q 13 Jul 2023 2023 Q2
Q1 2022 44,693,812 01 Dec 2021 28 Feb 2022 10-Q 13 Apr 2023 2023 Q1
Q3 2021 44,374,389 +27,436,455 +162% 01 Jun 2021 31 Aug 2021 10-Q 06 Oct 2022 2022 Q3
Q2 2021 43,804,066 +40,072,228 +1074% 01 Mar 2021 31 May 2021 10-Q 07 Jul 2022 2022 Q2
Q3 2020 16,937,934 01 Jun 2020 31 Aug 2020 10-Q 14 Oct 2021 2021 Q3
Q2 2020 3,731,838 01 Mar 2020 31 May 2020 10-Q 13 Jul 2021 2021 Q2

Nurix Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 86,666,907 +19,546,641 +29% 01 Dec 2024 30 Nov 2025 10-K 28 Jan 2026 2025 FY
2024 67,120,266 +12,782,365 +24% 01 Dec 2023 30 Nov 2024 10-K 28 Jan 2026 2025 FY
2023 54,337,901 +5,729,911 +12% 01 Dec 2022 30 Nov 2023 10-K 28 Jan 2026 2025 FY
2022 48,607,990 +5,712,607 +13% 01 Dec 2021 30 Nov 2022 10-K 28 Jan 2025 2024 FY
2021 42,895,383 01 Dec 2020 30 Nov 2021 10-K 09 Feb 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.